Company Name: Target Corp.
Public Availability Date: February 12, 2008
Document Sections:
INQUIRY LETTER
APPENDIX 1
APPENDIX 2
INQUIRY LETTER
STAFF REPLY LETTER
[INQUIRY LETTER]
January 17, 2008
Securities and Exchange Commission
Office of Chief Counsel
Division of Corporate Finance
100 F Street, N.E.
Washington, DC 20549
Re: Target Corporation 2008 Annual Meeting - Shareholder Proposal Submitted by
the AFL-CIO
Ladies and Gentlemen:
Pursuant to Rule 14a-8(j) under the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), this letter requests that the Staff of the Division of
Corporate Finance concur with our view that, for the reasons stated below, the
proposal dated December 3, 2007 (the "Proposal") from the American Federation of
Labor and Congress of Industrial Organizations (the "Proponent") may be omitted
from the proxy materials for the 2008 Annual Meeting of Shareholders (the "2008
Annual Meeting") of Target Corporation (the "Company"). The Proposal is attached
to this letter as Exhibit A.
GENERAL
The 2008 Annual Meeting is scheduled to be held on or about May 22, 2008. The
Company intends to file its definitive proxy materials with the Securities and
Exchange Commission on or about April 7, 2008, and to commence mailing to its
shareholders on or about such date.
In accordance with Rule 14a-8(j) promulgated under the Exchange Act, enclosed
are:
1. Six copies of this letter, which includes an explanation of why the Company
believes it may exclude the Proposal; and
2. Six copies of the Proposal.
A copy of this letter is also being sent to the Proponent as notice that the
Company intends to exclude the Proposal from the Company's proxy materials for
the 2008 Annual Meeting.
TEXT OF PROPOSAL
The Proposal states:
Resolved: Shareholders request that the Board of Directors (the "Board") of
Target Corporation ("Target," or the "Company") adopt a policy addressing
conflicts of interest involving board members with health industry affiliations.
The policy shall provide for recusal from voting and from chairing board
committees when necessary. The policy shall address conflicts associated with
Company involvement in public policy issues related to Board members' health
industry affiliations and shall be explicitly integrated with the Company's
existing policies regarding related party transactions. For the purposes of this
policy, "board members with health industry affiliations" means any Board member
who is also a director, executive officer or former executive officer of a
company or trade association whose primary business is in the health insurance
or pharmaceutical industries.
REASONS FOR EXCLUSION OF PROPOSAL
The Company believes that the Proposal may be properly excluded from its proxy
material for the 2008 Annual Meeting on three separate grounds:
Under Rule 14a-8(i)(7) as relating to the conduct of the ordinary business
operations of the Company.
Under Rule 14a-8(i)(10) because the Company has already substantially
implemented the Proposal.
Under 14a-8(i)(3) because it is vague and indefinite and, thus, misleading in
violation of Rule 14a-9.
1. The Proposal May Be Excluded Under Rule 14a-8(i)(7) as Relating to the
Conduct of the Ordinary Business Operations of the Company.
A. The Proposal Relates to the Ordinary Business Operations of the Company
Under Rule 14a-8(i)(7), a company may properly exclude a proposal dealing with a
matter relating to the conduct of the registrant's ordinary business operations
and not involving significant social policy issues. The policy underlying Rule
14a-8(i)(7) is "to confine the resolution of ordinary business problems to
management and the board of directors, since it is impracticable for
shareholders to decide how to solve such problems at an annual shareholders
meeting." SEC Rel. No. 34-40018 (May 21, 1998). This underlying policy rests on
two central considerations. First, certain tasks are so fundamental to
management's ability to run a company on a day-to-day basis that they are not
proper subjects for shareholder proposals. The second consideration "relates to
the degree to which the proposal seeks to `micro-manage' the company by probing
too deeply into matters of a complex nature upon which shareholders, as a group,
would not be in a position to make an informed judgment." SEC Rel. No. 34-40018
(May 21, 1998). For the reasons presented below, the Proposal falls within the
parameters of the ordinary business exception contained in Rule 14a-8(i)(7) and
the Company may exclude the Proposal on that basis.
The Division has consistently determined that proposals that relate to the
promulgation of, and monitoring of compliance with, codes of ethics may be
excluded pursuant to Rule 14a-8(i)(7) because they relate to matters involving
ordinary business operations. See, e.g., Verizon Communications Inc. (February
23, 2007) (proposal to form a corporate responsibility committee); Lockheed
Martin Corp. (January 29, 1997) (proposal requesting the audit and ethics
committee to determine whether the company has an adequate legal compliance
program and prepare a report); AT&T Corp. (January 16, 1996) (ordinary business
operations exception applied to a proposal requesting that the company's board
of directors initiate a review of certain employment practices in light of the
company's code of ethics); and NYNEX Corp. (February 1, 1989) (proposal related
to the formation of a special committee of the registrant's board of directors
to revise the existing code of corporate conduct). The Division has also
determined that proposals relating to conflict of interest transactions may be
excluded pursuant to Rule 14a-8(i)(7) because they relate to matters involving
ordinary business operations. See Genetronics Biomedical Corporation (April 4,
2003) (proposal that the company shall not do business with any company in which
a board member has a financial stake was considered ordinary business because it
included matters relating to "non-extraordinary transactions").
Ensuring compliance with state and federal legal and regulatory requirements and
the rules of the New York Stock Exchange ("NYSE"), as well as a company's
internal policies, is a fundamental management function. As discussed in more
detail on the Company's website at www.target.com under "InvestorsCorporate
Governance," the Company has for decades been supporting sound corporate
governance practices. In particular, the Governance Committee of the Company's
Board, which consists of all non-management directors, has oversight
responsibility for this critical management function.
B. The Form of the Proposal Should Not Be Elevated Above Its Substance
The Proposal is excludable because it pertains to health care costs and, thus,
employee benefits. Although the proposal is couched in terms of Board policies
and procedures regarding potential director conflicts of interest and
related-party transactions, it is clear from the Proposal's references to
"health costs" as the "biggest economic challenge" that the cost of employee
health care is the primary subject of the Proposal. The Division has
consistently agreed that proposals pertaining to a company's health care costs
are excludable under Rule 14a-8(i)(7). For example, last year the Division
concurred that proposals requesting companies to report on the implications of
health care expenses and how the companies would address this public policy
issue without compromising the health and productivity of their workforce
involved a matter of ordinary business (i.e., employee benefits). See, e.g.,
General Motors Corporation (April 11, 2007); Target Corporation (February 27,
2007); and Kohl's Corporation (January 8, 2007). The substance of the Proposal
focuses on the same employee benefit cost concerns as the proposals mentioned
above and therefore should be excludable.
C. The Proposal Is Directed at Involving the Company in the Political Process
The Division has interpreted Rule 14a-8(i)(7) to support the exclusion of
proposals which are "directed at involving [the company] in the political ...
process relating to an aspect of [the company's] operation." See International
Business Machines Corporation (Jan. 21, 2002); Chrysler Corporation (Feb. 10,
1992) (proposal to support the establishment of universal health coverage).
The Proponent is openly involved in "political mobilization" and seeks to "build
an army of a million union activists to organize for changing the nation's
broken health care system." AFL-CIO Declares '08 Elections a Mandate for High
Quality Heath Care for All by '09, Press Release (August 29, 2007). Although
styled as a request for a conflict of interest policy, the Proposal refers
specifically to the Company's "involvement in public policy issues" relating to
the health industry, which is a politically motivated attempt to involve the
Company into a national debate on health care reform.
For the foregoing reasons, the Company respectfully submits that the Proposal
may be excluded from its 2008 proxy materials because it deals with matters
relating to the Company's ordinary business operations.
2. The Proposal May Be Excluded Under Rule 14a-8(i)(10) Because the Company Has
Substantially Implemented the Proposal.
The Company believes that the Proposal may be excluded pursuant to Rule
14a-8(i)(10) because it has been substantially implemented by the Company. Rule
14a-8(i)(10) permits a company to exclude from its proxy materials a shareholder
proposal that has already been substantially implemented. The Company has
substantially implemented the Proposal through a combination of the Conflicts of
Interest policy in the Company's Business Conduct Guide and a detailed state law
provision governing director conflicts of interest to which the Company is
subject.
As an NYSE-listed company, the Company is required under NYSE's listing
standards to have a code of business conduct and ethics applicable to its
directors, officers and employees that covers conflicts of interest, among other
topics. The Company's Business Conduct Guide, available on the Company's website
at www.target.com under "InvestorsCorporate Governance," has a specific policy
on Conflicts of Interest, which is attached to this letter as Exhibit B. This
policy, which is applicable to directors, states that a person subject to the
policy must avoid any situation in which that person's personal interests may
conflict with the Company's and must immediately disclose any actual or
perceived conflicts that exist.
The relevant state law, Minn. Stat. Sec. 302A.255, which is attached to this
letter as Exhibit C, provides more specific requirements for conflicts involving
directors. Specifically, this statute requires that any contract or transaction
between a corporation and one of its directors, or between a corporation and an
organization in which the director serves as a director, officer or legal
representative or has a material financial interest, is:
fair and reasonable to the corporation;
approved by a supermajority vote of shareholders; or
approved by the other directors, with the conflicted director recusing himself
or herself from the vote.
The Proposal requests that the Board adopt a policy "addressing conflicts of
interest involving Board members with health industry affiliations." The
Company's Business Conduct Guide and applicable state law address all conflicts
of interest in all industries, not merely conflicts involving health industries.
The Company's Business Conduct Guide, together with applicable state law, also
addresses each element of the Proposal:
The Proposal applies to "any Board member who is also a director, executive
officer or former executive officer" in a health industry company. The Business
Conduct Guide governs situations where a director's personal interests are
adverse to the interests of the Company, and state law would apply to any
contract or transaction with an organization in which a director serves as a
director, officer or legal representative or has a material financial interest.
The Proposal would establish a policy to "provide for recusal from voting and
from chairing board committees when necessary." State law requires that in the
case of any conflict, a director may not vote on the matter unless the contract
or transaction is otherwise fair and reasonable to the corporation.
The Proposal's policy would "address conflicts associated with Company
involvement in public policy issues related to Board members' health industry
affiliations and shall be explicitly integrated with the Company's existing
policies regarding related party transactions." Under the Company's existing
related persons transactions policy, all Company transactions, arrangements and
relationships involving more than $120,000 in which a Related Person has any
direct or indirect material interest must be approved by the Audit Committee of
the Board of Directors. This would certainly apply to any interest involving the
health industry.
As a practical matter, a conflict of interest policy cannot possibly reference
every potential industry with which a director may conceivably have a conflict.
As such, a health industry conflict policy would be entirely duplicative of the
existing policy in the Business Conduct Guide and applicable state law.
Moreover, the Business Conduct Guide and state law already provide adequate
safeguards for shareholders to deal with any conflicts that may exist. For this
reason, the Company respectfully submits that the Proposal has been
substantially implemented and should be excluded.
3. The Proposal May Be Excluded Under Rule 14a-8(i)(3) Because It Is Vague and
Indefinite and, thus, Misleading in Violation of Rule 14a-9.
Rule 14a-8(i)(3) permits the exclusion of a shareholder proposal if the proposal
is contrary to any of the proxy rules or regulations, including Rule 14a-9. Rule
14a-9(a) provides that "[n]o solicitation ... shall be made by means of any
proxy statement ... containing any statement which, at the time and in light of
the circumstances under which it is made, is false or misleading with respect to
any material fact, or which omits to state any material fact necessary in order
to make the statements therein not false or misleading...." The Division has
interpreted Rule 14a-8(i)(3) to permit the exclusion of a shareholder proposal
that is vague, indefinite and, therefore, materially false or misleading if "the
resolution contained in the proposal is so inherently vague or indefinite that
neither the stockholders voting on the proposal, nor the company in implementing
the proposal (if adopted), would be able to determine with any reasonable
certainty exactly what actions or measures the proposal requires." Staff Legal
Bulletin No. 14B (September 15, 2004).
Furthermore, proposals may be excluded as vague and indefinite where they fail
to define critical terms or otherwise provide guidance to the board of directors
regarding the proposal's implementation. See, e.g., International Business
Machines Corporation (February 2, 2005) (permitting exclusion of a proposal that
was subject to multiple interpretations, therefore making it misleading due to
vagueness and indefiniteness); Peoples Energy (November 23, 2004) (permitting
exclusion of a proposal that employed an undefined legal standard, therefore
making it misleading due to vagueness and indefiniteness); Procter & Gamble Co.
(October 25, 2002) (permitting exclusion of a proposal where the company argued
that neither the shareowners nor the company would know how to implement the
proposal).
Specifically, we believe that the Proposal is vague and indefinite in the
context of the Company's existing conflict of interest policies. The Proposal is
entirely silent on how to "adopt a policy addressing conflicts of interest
involving Board members with health industry affiliations" where an existing
conflict of interest policy already exists. Neither the Company nor its
shareholders would be able to determine with reasonable certainty whether the
Proposal required a new conflict of interest policy, a separate health industry
policy, amendments to the existing policy, or some other implementation measure.
Moreover, the Proposal does not discuss those circumstances that should be
viewed as giving rise to conflicts of interest, including the scope, depth and
nature of any relationships that may give rise to potential conflicts. As a
result, neither shareholders in voting on the Proposal, nor the Company in
implementing the Proposal (if Company were to do so), would be able to determine
with any reasonable certainty the potential conflicts of interests to which the
Proposal should apply.
Because the Proposal is vague and indefinite, and therefore misleading, the
Company respectfully submits that the Proposal may be excluded under Rule
14a-8(i)(3) as a violation of the proxy rules of 14a-9(a).
CONCLUSION
On the basis of the foregoing, the Company respectfully requests that the
Division concur that the Proposal may be excluded from the Company's proxy
materials for the 2008 Annual Meeting. Based on the Company's timetable for the
2008 Annual Meeting, a response from the Division by February 20, 2008 would be
appreciated.
Should you have any questions, or should you require any additional information
regarding the foregoing, please do not hesitate to contact me at 612/696-0876.
Please acknowledge receipt of this letter by stamping and returning the enclosed
receipt copy of this letter. Thank you for your prompt attention to this manner.
Very truly yours,
/s/
David L. Donlin,
Assistant General Counsel
Target Corporation
[APPENDIX 1]
Exhibit A
December 3, 2007
By UPS Next Day Air
Mr. Timothy R. Baer, Corporate Secretary
Target Corporation
1000 Nicollet Mall
Minneapolis, Minnesota 55403
Dear Mr. Baer:
On behalf of the AFL-CIO Reserve Fund (the "Fund"), I write to give notice that
pursuant to the 2007 proxy statement of Target Corporation (the "Company"), the
Fund intends to present the attached proposal (the "Proposal") at the 2008
annual meeting of shareholders (the "Annual Meeting"). The Fund requests that
the Company include the Proposal in the Company's proxy statement for the Annual
Meeting. The Fund is the beneficial owner of 600 shares of voting common stock
(the "Shares") of the Company and has held the Shares for over one year. In
addition, the Fund intends to hold the Shares through the date on which the
Annual Meeting is held.
The Proposal is attached. I represent that the Fund or its agent intends to
appear in person or by proxy at the Annual Meeting to present the Proposal. I
declare that the Fund has no "material interest" other than that believed to be
shared by stockholders of the Company generally. Please direct all questions or
correspondence regarding the Proposal to me at (202) 637-5379.
Sincerely,
/s/
Daniel F. Pedrotty
Director
Office of Investment
DFP/ms
opeiu #2, afl-cio
Attachment
[APPENDIX 2]
Resolved: Shareholders request that the Board of Directors (the "Board") of
Target Corporation ("Target," or the "Company") adopt a policy addressing
conflicts of interest involving board members with health industry affiliations.
The policy shall provide for recusal from voting and from chairing board
committees when necessary. The policy shall address conflicts associated with
Company involvement in public policy issues related to Board members' health
industry affiliations and shall be explicitly integrated with the Company's
existing policies regarding related party transactions. For the purposes of this
policy, "board members with health industry affiliations" means any Board member
who is also a director, executive officer or former executive officer of a
company or trade association whose primary business is in the health insurance
or pharmaceutical industries.
Supporting statement
Target directors Roxanne S. Austin and James A. Johnson are also directors of
Abbott Laboratories and UnitedHealth Group Incorporated, respectively. Target
director Derica W. Rice is also the Senior Vice President and CFO of Eli Lilly
and Company. Mr. Rice is on the Corporate Governance Committee of Target's
Board. Mr. Johnson is Chair of the Corporate Governance Committee. As of
September 28, 2007, Mr. Johnson's holdings in UnitedHealth Group Incorporated
and Ms. Austin's holdings in Abbott Laboratories both outweigh their holdings in
our Company.
In our view, our Company's existing director independence policies do not
adequately address the financial and professional interests of our Company's
health industry affiliated directors, nor does our Company require that health
industry affiliated directors recuse themselves from Board decisions related to
pharmaceutical or health insurance issues that are significant social policies.
Access to affordable, comprehensive health insurance is the most significant
social policy issue in America, according to polls by NBC News/The Wall Street
Journal, the Kaiser Foundation, and The New York Times/CBS News. John
Castellani, president of the Business Roundtable has stated that 52 percent of
his members say health costs represent their biggest economic challenge,
explaining that "The current situation is not sustainable in a global,
competitive workplace." (BusinessWeek, 7/3/2007)
Health care costs could be cut by as much as $1,160 per employee if Congress
enacted universal health insurance and required Medicare to negotiate
prescription drug prices directly with pharmaceutical companies. (Dr. Kenneth
Thorpe, Emory University, 2007)
We are concerned that the financial and professional interests of health
industry affiliated directors could improperly influence our Company's position
on significant social policy issues that could benefit the Company.
We believe that chairing committees or voting by health industry affiliated
directors on Board decisions on health issues may create the appearance of a
conflict of interest. In our opinion, this proposal will help prevent health
industry affiliated directors from compromising their duty of loyalty to our
Company's shareholders.
[INQUIRY LETTER]
February 11, 2008
Office of Chief Counsel
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Re: Target Corporation's Request to Exclude Proposal Submitted by the AFL-CIO
Reserve Fund
Dear Sir/Madam:
This letter is submitted in response to the claim of Target Corporation
("Target" or the "Company"), by letter dated January 17, 2008, that it may
exclude the shareholder proposal ("Proposal") of the AFL-CIO Reserve Fund
("Fund" or the "Proponent") from its 2008 proxy materials.
I. Introduction
Proponent's shareholder Proposal to Target urges:
that the Board of Directors adopt a policy addressing conflicts of interest
involving board members with health industry affiliations. The policy shall
provide for recusal from voting and from chairing board committees when
necessary. The policy shall address conflicts associated with company
involvement in public policy issues related to their health industry
affiliations and shall be explicitly integrated with the company's existing
policies regarding related party transactions. For the purposes of this policy,
"board members with health industry affiliations" means any Board member who is
also a director, executive officer or former executive officer of a company or
trade association whose primary business is in the health insurance or
pharmaceutical industries (emphasis added).
Target's letter to the Commission stated that it intends to omit the Proposal
from its proxy materials to be distributed to shareholders in connection with
the Company's 2008 annual meeting of shareholders. Target argues that the
Proposal is in violation of:
Rule 14a-8(i)(7) as an ordinary business matter, despite the fact that the
Proposal addresses a significant social policy issue,
Rule 14a-8(i)(10) because Target has substantially implemented the Proposal,
even though the statutory, regulatory and Company Code of Conduct for directors
is inapplicable to conflicts of interest involving significant social policy
issues, and
Rule 14a-8(i)(3) because it is vague and indefinite, and thus misleading in
violation of Rule 14a-9, even though American Express, Electronic Data Systems
(EDS) and McGraw-Hill Companies, which received the same proposal, simply
amended their conflicts of interest policies to prevent the conflicts of
interest at issue.
The Proposal was carefully crafted to address the significant social policy
issue of health care reform and the conflicts of interest that arise when health
industry affiliated directors vote or chair board actions on this issue. The
statutory and regulatory requirements on director conflicts of interest cited by
Target, together with the Company's own policies and procedures on conflicts of
interest, address commercial transactions, not conflicts of interest on
significant social policy issues.
II. Health industry affiliated director conflicts of interest are significant
social policy issues and may not be excluded under Rule 14a-8(i)(7).
A. Health care reform is a significant social policy issue.
The Commission stated in Exchange Act Release No. 40018 that "proposals that
relate to ordinary business matters but that focus on `sufficiently significant
social policy issues ... would not be excludable, because the proposals would
transcend day-to-day business matters....'" The Proposal before Target is just
such a proposal. It addresses the significant social policy issue of health care
reform and conflicts of interest that are presented by the Company's health
industry affiliated directors on this issue. The Proposal does not ask the
Company to provide any information or reports on its internal operations, nor
does it attempt to micromanage the Company. Instead it urges the Board to
integrate the Company's existing policies with an amended policy to protect the
Company and shareholders from health industry affiliated director conflicts of
interest.
Health care reform is, in fact, the most important domestic issue in America.
Public opinion polls by The Wall Street Journal/NBC News, the Kaiser Foundation
and The New York Times all document its significance. In the latest Wall Street
Journal/NBC News poll, for example, 52 percent of Americans "say the economy and
health care are most important to them in choosing a president, compared with 34
percent who cite terrorism and social and moral issues. ... That is the reverse
of the percentages recorded just before the 2004 election. The poll also shows
that voters see health care eclipsing the Iraq war for the first time as the
issue most urgently requiring a new approach." 1
Many businesses now cite health care costs as their biggest economic challenge.
John Castellani, president of the Business Roundtable, has called health care
reform a top priority for business and Congressional action." 2 In September,
the CEOs of Kelly Services and Pitney Bowes, Inc., together with GE's Global
Health Director, called on Congress to enact health care reform.3 They joined
other leading business coalitions, including the National Coalition on Health
Care and the National Business Group on Health. The latter's membership consists
of 245 major companies, including 60 of the Fortune 100.4 Each organization
maintains that the cost of health care for business is now greater than it
should be and will continue to rise as long as 47 million Americans who have no
health insurance remain without coverage.
Other leading business organizations have recently announced their support for
health care reform: Divided We Fail, a coalition of the AARP, the Business
Roundtable, the Service Employees International Union (SEIU) and the National
Federation of Independent Business, states that it will "make access to quality,
affordable health care and long-term financial security top issues in the
national political debate." 5 In addition, Wal-Mart has joined with SEIU calling
on Congress to enact health care reform.6
Underscoring the significance of health care reform as a major social policy
issue, the American Cancer Society has taken the unprecedented step of
redirecting its entire $15 million advertising budget "to the consequences of
inadequate health care coverage" in the United States.7
B. Health industry affiliated director conflicts on health care reform are
significant social policy issues.
Health industry affiliated director conflicts of interest are themselves a
significant policy issue in the media and in Congress. During Congressional
consideration of amendments to the Hatch-Waxman Act, for example, directors at
both Verizon and Georgia-Pacific were instrumental in terminating each company's
support for and involvement in Business for Affordable Medicine, a business
coalition supporting federal legislation to strengthen the Act.8 The coalition
had been organized by the governors of 12 states, Verizon, Georgia-Pacific and
other major corporations to reduce expenditures on prescription drugs, a major
problem for business and state Medicaid programs. The Congressional Budget
Office estimated that the legislation would reduce total spending on
prescription drugs by $60 billion, or 1.3 percent, over the next 10 years. An
examination of Verizon's proxy revealed that its CEO, Ivan Seidenberg, the
chairman of its Human Resources Committee, Walter Shipley, John R. Stafford,
retired CEO of Wyeth, and Richard L. Carrion, were each directors of Wyeth,
which successfully lobbied Verizon to end its involvement in the coalition.9
At General Motors, where health care costs have long been a central concern,
three of the eleven independent directors on the board are directors of
pharmaceutical companies. The Company's presiding director, George Fisher, also
serves as a director of Eli Lilly and Company. Percy N. Barnevik, a director
since 1997, retired as CEO of AstraZeneca PLC in 2004 and serves as Chairman of
GM's Public Policy Committee. Director Karen Katen retired as executive vice
president of Pfizer in 2007, served as an officer of PhRMA and continues to
serve as chair of the Pfizer Foundation. Each director's holdings in Eli Lilly,
AstraZeneca and Pfizer, respectively, vastly outweigh his or her holdings in GM.
In 2007, The New York Times reported that GM was the only U.S. auto company
purchasing the brand-name drug, Nexium, manufactured by AstraZeneca, at a cost
to GM of $110 million per year. Senior management and labor leaders at GM had
decided to eliminate Nexium from the GM formulary.10 That decision was
overturned, according to senior labor and management leaders at GM, after the GM
board of directors reviewed it. At the same time, and despite its extensive
federal legislative activity, GM failed to take any action to support
legislation to reform the Medicare prescription drug program to require
prescription drug price negotiations between pharmaceutical companies and the
federal government.11
Conflicts of interest among health industry affiliated directors have also been
documented by Chrysler Corporation's former vice president of public policy,
Walter B. Maher. Writing in the American Journal of Public Health, Maher
described how "a representative of the insurance industry" [the CEO of
Prudential Insurance] successfully blocked Chrysler Corporation's efforts to
persuade Business Roundtable members to support health care reform." 12
At least 21 major companies (Attachment "A"), including Target, have multiple
health industry affiliated directors serving on their boards of directors.13
1. Companies now recognize health care reform as a significant social policy
issue and have amended their conflict of interest policies for health industry
affiliated directors accordingly.
At the same time Proponent filed the Proposal at Target, Proponent filed
virtually identical proposals on this same issue at the American Express
Company, the McGraw-Hill Companies and EDS. In addition, proponents filed
proposals calling upon companies to adopt principles on the significant social
policy issue of health care reform at IBM, General Electric and Bristol-Meyers
Squibb. Instead of seeking No-Action Letters from the Commission to exclude
these proposals, American Express, McGraw-Hill, IBM, General Electric and
Bristol-Meyers Squibb each commenced dialogues with proponents and each has
agreed to revise director conflicts of interest policies or issue corporate
statements of principles for health care reform.14 Proponents have agreed to
withdraw the proposals and, in the case of Bristol-Meyers Squibb, the company
has withdrawn its request to the Commission for a No-Action Letter.
Finally, EDS, whose request for a No-Action Letter was granted, Electronic Data
Systems Corporation (January 24, 2008), nevertheless agreed to amend its
conflict of interest policies after dialogue with the Proponent.15
C. The Proposal presents a significant public policy issue that does not relate
to Target's ordinary business operations.
Rule 14a-8(i)(7) permits a company to exclude a proposal if it "deals with a
matter relating to the company's ordinary business operations." The Commission
has stated that a proposal that is otherwise excludable under the ordinary
business exclusion is includable, however, if it raises a significant policy
issue. (Securities Exchange Act Release No. 40,018 (May 21, 1998).)
Target appears to have ignored the fact that the Proposal specifically states
that the Proposal urges the Board to adopt a policy addressing:
conflicts associated with company involvement in public policy issues related to
their [directors'] health industry affiliations and shall be explicitly
integrated with the company's existing policies regarding related party
transactions (emphasis added).
Instead, the Company repeatedly misconstrues the Proposal as a conflicts of
interest policy request that micromanages ordinary business matters of employee
benefits. It does nothing of the kind. The Proposal addresses health care reform
as an external, significant social policy issue facing the Nation and the
Company. The Proposal focuses on health industry affiliated director conflicts
associated with Company involvement in this significant social policy issue.
Target directors Roxanne S. Austin and James A. Johnson are also directors of
Abbott Laboratories and UnitedHealth Group Incorporated, respectively. Target
director Derica W. Rice is also the senior vice president and CFO of Eli Lilly
and Company. Mr. Rice is on the Corporate Governance Committee of Target's
board. Mr. Johnson is chair of the Corporate Governance Committee. As of
September 28, 2007, Mr. Johnson's holdings in UnitedHealth Group Incorporated
and Ms. Austin's holdings in Abbott Laboratories both outweighed their holdings
in the Company.
As pharmaceutical and health insurance company directors, however, Ms. Austin
and Messrs. Johnson and Rice must routinely take positions on the significant
social policy issue of health care reform that are in conflict with the
interests of Target. For example, Abbott and Eli Lilly are opposed to any
amendments to Medicare that would empower the federal government to negotiate
prices of prescription drugs with pharmaceutical companies, or to establish a
Medicare formulary. With the exception of pharmaceutical companies like Abbot
and Eli Lilly, Target and all other businesses would realize significant savings
from such an amendment to Medicare because the prices of prescription drugs
would decline substantially.16
It is precisely because health care reform is a significant social policy issue
that Target's health industry affiliated directors must recuse themselves from
chairing committees or voting on this issue. Target's existing policies and
practices do not require directors to recuse themselves because the issue is not
considered to be one of the personal financial interests covered by the
Company's existing policies and practices. Unless they recuse themselves from
voting or chairing committees, however, there is at least the appearance of a
director conflict of interest at Target.
The Company cites Verizon Communications, Inc., 2007 SEC No-Act. LEXIS 268
(February 23, 2007). The proposal before Verizon, however, involved a request to
create a "Corporate Responsibility Committee" to monitor the extent to which
Verizon lives up to its claims pertaining to integrity, trustworthiness and
reliability." The breadth of that proposal and its obvious involvement in
ordinary business is in stark contrast to the Proposal before Target, which goes
to the matter of a significant social policy issue that is not a matter of
ordinary business.
Target cites Lockheed Martin Corporation, 1997 SEC No-Act. LEXIS 208 (January
29, 1997). There, the proposal mandated the board of directors to evaluate
whether the company had a legal compliance program that adequately reviewed
conflicts of interest and the hiring of former government officials and
employees and to prepare a report on its findings. There was nothing in the
Lockheed proposal that focused on public policy issues. Instead, the Lockheed
proposal called for a broad review of the company's ordinary business
operations.
AT&T Corporation, 1996 SEC No-Act. LEXIS 41 (January 16, 1996), involved a
proposal asking the board of directors to initiate a review of the standards and
practices in the company's maquiladora operations and prepare a report to be
made available to shareholders, including recommendations for changes. The
Proposal before Target contains no call for a report or a review of its
standards and practices on labor and production operations. The Proposal is a
clear request for a conflicts of interest policy dealing with public policy
issues before the board of directors.
NYNEX Corporation, 1989 SEC No-Act. LEXIS 95 (February 1, 1989), was a proposal
calling for the formation of a special committee of the board of directors to
revise the existing code of corporate conduct. The proposal called for special
assistance to needy customers and safety protections for company employees. The
Proposal before Target is narrowly focused on public policy issues related to
directors with health industry affiliations.
Genetronics Biomedical Corporation, 2003 SEC No-Act. LEXIS 527 (April 4, 2003),
involved a conflicts of interest proposal, but Target conveniently ignores the
fact that the Commission's decision specifically noted that the proposal before
Genetronics attempted to deal with "all financial conflicts of interest"
involving directors and that it "appears to include matters relating to
non-extraordinary transactions." The Proposal before Target, however, is
carefully crafted to address only health industry affiliated director conflicts
of interest affecting the significant social policy issue of health care reform.
D. The Proposal's form and substance address a significant social policy issue
rather than an ordinary business matter.
Target mistakenly argues that the Proposal is nothing more than an attempt to
deal with the Company's health costs, a matter of ordinary business. Yet the
plain language of the Proposal shows that it addresses the significant social
policy issue of health care reform, not routine health care cost matters. Cost
is a concern in any consideration of a significant social policy issue, of
course, but this fact does not make the issue a matter of ordinary business.
Consider, for example, the matter of labor and human rights, a significant
social policy issue. Cost concerns are certainly an issue because wage rates and
risk management require spending. That did not render proposals seeking adoption
of labor and human rights principles excludable. McDonald's Corporation, 2007
SEC No-Act. LEXIS 378 (March 22, 2007); Costco Wholesale Corporation, 2004 SEC
No-Act. LEXIS 806 (October 26, 2004).
The same is true for the adoption of principles on health care reform, another
significant social policy issue. United Technologies Corporation, 2008 SEC
No-Act. LEXIS ___ (January 31, 2008), involved a proposal urging the board of
directors to adopt principles on the significant social policy issue of health
care reform. The Commission rejected the company's argument that the proposal
could be excluded on ordinary business grounds.
In Ford Motor Company, 2007 SEC No-Act. LEXIS 296 (March 1, 2007), the Staff
agreed that a proposal requesting that the board prepare a report "examining the
implications of rising health care expenses and how Ford is addressing this
issue without compromising the health and productivity of its workforce," could
not be excluded as ordinary business under rule 14a-8(i)(7). The proposal
requested a report focused exclusively on health care costs as a significant
social policy issue. Both the proposal and the supporting statement contained
extensive documentation on health care costs. Both carefully framed the issue as
one that in no way involved reporting on the internal risks posed to Ford's
ordinary business, including its employee benefits operations.
The Company, however, cites Staff decisions on proposals that centered on
matters of internal risk assessment and company finances relating to employee
benefits plans. General Motors Corporation, 2007 SEC No-Act. LEXIS 446 (April
11, 2007), involved a report on GM's health care costs for GM employees and
retirees and their dependents and their implication for various policy
developments in health care. Target Corporation, 2007 SEC No-Act. LEXIS 290
(February 27, 2007), and Kohl's Corporation, 2007 SEC No-Act. LEXIS 5 (January
8, 2007), involved the same proposal, calling for a report on health care costs
at each company. Unlike the Proponent's Proposal, which calls for the adoption
of amendments to conflicts of interest policies regarding a significant social
policy issue, the health care reports called for by the proposals in General
Motors Corporation, Target Corporation and Kohl's would have required each
company to conduct internal risk assessments.
Unlike the Proponent's Proposal, which calls for the adoption of principles on a
significant social policy issue, the health care reports called for by the
proposals in Target Corporation would have required each company to conduct
internal risk assessments.
E. The Proposal is directed at protecting the Company's reputation on a
significant social policy issue, not involving Target in the political process.
The AFL-CIO Reserve Fund is solely concerned with protecting the value of its
investments for the retirement security of its members. The Proposal is designed
to do just that, by asking the Company to take action to protect its interests
on the significant social issue of health care reform. Health industry
affiliated directors have interests that diverge from those of Target on this
issue. Consequently, in considering whether Target should adopt its own
principles for health care reform, Target's directors must act with the utmost
independence. They cannot do so as health industry affiliated directors when
they vote or chair board committees considering the adoption of principles on
health care reform. That is the essence of this proposal, not lobbying. While
the AFL-CIO, not the AFL-CIO Reserve Fund, is, of course, engaged in political
and legislative activity, the Fund is not. Target, however, wrongly imputes the
actions of the AFL-CIO to the Fund and, by inference to the Proposal itself.
That assertion is in error.
Whether Target engages in political or legislative activity is a matter of
ordinary business for the Company, not shareholders. All the Proposal seeks to
do is to urge the board to take action on a significant social policy issue and
to do so as independent directors, free from conflicts of interest.
International Business Machines Corporation, 2002 SEC No-Act. LEXIS 85 (January
21, 2002), cited by the Company, involved a proposal that called upon IBM to:
share with its stockholders the estimated average annual cost for employee
health benefits in the United States versus the next five countries with the
largest number of IBM employees" and commence a lobbying campaign for national
health insurance.
Proponent's Proposal contains nothing that would require the sharing of health
benefits costs information with shareholders. Nor is there any request to the
Company to commence a lobbying campaign for national health insurance. Instead,
the Proposal asks the Company to adopt a statement of principles for health care
reform. While the Proposal does state Proponent's opinion that health care
reform is a significant issue in the presidential campaign of 2008, it merely
requests the board to adopt principles for health care reform. It contains no
request for other action. It is entirely up to the Company's board of directors
and management to take any actions they may deem necessary on health care reform
or, for that matter, on any other matter relating to its internal operations
with respect to health care benefits.
The Company would have the Commission believe that the Proposal requires Target
to engage in "the political or legislative process" on "a matter of ordinary
business." First, as Proponent has demonstrated above, the Proposal urges the
board of directors to adopt principles on a significant social policy issue,
health care reform. The evidence continues to mount that health care reform is a
significant social policy issue.17 Indeed, Bristol-Meyers Squibb, which
initially sought the Commission's approval to exclude a nearly identical
proposal on ordinary business grounds, has withdrawn its request and has adopted
principles for health care reform. IBM, which has successfully opposed proposals
calling for reports on health care costs and lobbying by the company, began a
dialogue with proponents that resulted in a statement of principles for health
care reform.
Second, the Proposal in no way urges the Company to involve itself in the
political or legislative process. Instead, it merely urges the board of
directors to adopt principles on this significant social policy issue, just as
GE, IBM and Bristol-Meyers Squibb have now done. The Company, however, citing
Chrysler Corporation, 1992 SEC No-Act. LEXIS 143 (February 10, 1992),
mischaracterizes the Proposal as one calling for the Company to participate in
the legislative or political process. But in Chrysler, the proposal specifically
called for lobbying.18 Proponent makes no such request.
III. Target has failed to demonstrate that it has substantially implemented the
Proposal because health industry affiliated conflicts of interest on significant
social policy issues are completely unaffected by the Company's existing
policies and its compliance with statutory and regulatory authorities.
The Company would have the Commission believe it has substantially implemented
the Proposal, thereby permitting its exclusion under Rule 14a-8(i)(10). A
comparison of the Proposal and Target's Business Conduct Guide clearly shows
that the Company has not adopted what the Proposal calls for, namely, a policy
addressing conflicts associated with company involvement in significant social
policy issues related to directors' health industry affiliations. Target's
Business Conduct Guide deals only with conflicts involving financial
transactions, not significant social policy issues.
NYSE Listing Standards, which Target cites as evidence of its substantial
implementation of the Proposal, addresses the "private interest" of a director
that may appear to be in conflict with the interests of the corporation as a
whole. The conflicts presented by health industry affiliated directors who deal
with the significant social policy issue of health care reform, however, are not
private transactional interests. The very nature of a significant social policy
issue is its public character. There is no personal financial stake involved.
While it is true, for example, that the market share of pharmaceutical companies
rose as a result of the Medicare Modernization Act, the personal, transactional
matters framed by NYSE Listing Standards would not pick up the conflict for
Target directors Roxanne S. Austin and James A. Johnson, who are also directors
of Abbott Laboratories and UnitedHealth Group Incorporated, respectively; or
Target director Derica W. Rice, who is also the senior vice president and CFO of
Eli Lilly and Company. Mr. Rice is on the Corporate Governance Committee of
Target's board. Mr. Johnson is chair of the Corporate Governance Committee.
Yet as Target directors, they have conflicts of interest if they fail to advise
the Company of their conflicts with respect to Target's position on, for
example, amendments to the Medicare Modernization Act that would empower the
federal government to negotiate prescription drug prices directly with
pharmaceutical companies.
Finally, the Company describes the director conflicts of interest provisions of
Minnesota Statute Section 302A.255 as another basis for its claim of substantial
implementation of the Proposal. But Minnesota law does not apply to director
conflicts involving a significant social policy issue. Instead, it deals only
with "material financial interests" and is framed in the context of commercial
transactions.
IV. The Company has failed to demonstrate that the Proposal is so inherently
vague And indefinite as to be misleading.
The Proposal urges the board of directors to:
adopt a policy addressing conflicts of interest involving board members with
health industry affiliations. The policy shall provide for recusal from voting
and from chairing board committees when necessary. The policy shall address
conflicts associated with Company involvement in public policy issues related to
Board members' health industry affiliations and shall be explicitly integrated
with the Company's existing policies regarding related party transactions. For
the purposes of this policy, "board members with health industry affiliations"
means any Board member who is also a director, executive officer or former
executive officer of a company or trade association whose primary business is in
the health insurance or pharmaceutical industries.
Each of the terms of the Proposal is carefully defined. Yet Target complains it
does not spell out "how to adopt a policy." Proponent filed virtually identical
proposals at American Express and McGraw-Hill. Each company amended its
conflicts of interest policies to make the reporting of all conflicts of
interest mandatory, rather than permissive and provided for mandatory recusal
from voting or chairing board committees affected by the conflict.
Target also complains that it would not know whether to adopt an entirely new
conflicts policy. Yet the Proposal specifically states that the amended policy
should be "explicitly integrated with the Company's existing policies regarding
related party transactions."
Target cites Commission decisions on No-Action Letters in The Proctor and Gamble
Company, SEC No-Action Letter, 202 SEC No-Act. LEXIS 768 (October 25, 2002), and
International Business Machines Corporation, 2005 SEC No-Act. LEXIS 139
(February 2, 2005), in support of its argument that the Proposal may be excluded
because it is so inherently vague and indefinite as to be misleading, with the
result that neither the shareholders nor the Company's board of directors would
be able to determine, with any reasonable amount of certainty, what action or
measures would be taken if the Proposal were implemented. A review of these
decisions, however, reveals they are not even remotely on point:
The Procter and Gamble Company excluded a shareholder proposal calling for the
establishment of a fund to provide legal assistance, witness protection and
other unspecified assistance to "victims of retaliation, intimidation and
troubles because they are stockholders/shareholders..."
International Business Machines Corporation excluded a shareholder proposal
calling for "the officers and directors responsible" for IBM's reduced dividend
payment to have "their pay reduced to the level prevailing in 1993" when the
change occurred.
Peoples Energy, 2004 SEC No-Act. LEXIS 854 (November 23, 2004), also cited by
Target, involved a proposal urging "the board of directors to take the necessary
steps to amend Peoples Energy's articles of incorporation and bylaws to provide
that officers and directors shall not be indemnified from personal liability for
acts or omissions involving gross negligence or `reckless neglect.'" Certainly
the terms of that proposal were ill-defined and the scope of the proposal so
broad as to be incomprehensible. The Proposal before Target is clear. It defines
the significant social policy issue, the affected directors and it states that
the policy amendment should be "explicitly integrated" with the Company's own
policies on related party transactions. Target's reliance upon Peoples Energy is
inapposite.
More relevant are Commission decisions on shareholder proposals requesting the
adoption of human rights principles and standards: McDonald's Corporation, Id.,
Peabody Energy Corporation, SEC No-Action Letter, 2006 SEC No-Act. LEXIS 316
(March 8, 2006), and E.I. du Pont de Nemours and Company, 2004 SEC No-Act. LEXIS
262 (February 11, 2004). In each case, the Staff denied requests to exclude the
proposals under Rule 14a-8(i)(3). Each of these decisions involved the adoption
of company principles or standards for human rights. As in the instant case,
they presented a clear request for board action on a significant social policy
issue and they presented principles or standards upon which the companies might
base their actions. Each company had the requisite power and competence to
determine the proper implementation of the principles. So, too, does Target.
V. Conclusion
Target has failed to meet its burden of demonstrating that it is entitled to
exclude the Proposal under Rule 14a-8(g).
The Proposal presents a significant social policy issue that transcends
day-to-day business matters at Target. It is, therefore, not excludable under
Rules 14a-(i)(7) and 14a-8(j).
A review of the Target Code of Conduct with respect to director involvement in
significant social policy issues clearly shows that Target has not substantially
implemented the Proposal. It may not be excluded under Rules 14a-8(i)(10) and
14a-8(j).
The Proposal is clear and it carefully defines its terms. The facxt that
American Express, McGraw-Hill and EDS have already implemented virtually
identical proposals is a clear demonstration of this fact. The Proposal may not
be excluded under Rule 14a-8(i)(3) and Rule 14a-8(i)(6).
Consequently, since Target has failed to meet its burden of demonstrating that
it is entitled to exclude the Proposal under Rule 14a-8(g), the Proposal should
come before Target's shareholders at the 2008 annual meeting.
If you have any questions or need additional information, please do not hesitate
to call me at 202-637-5335. I have enclosed six copies of this letter for the
Staff, and I am sending a copy to Counsel for the Company.
Sincerely,
/s/
Robert E. McGarrah, Jr.
Counsel
Office of Investment
REM/ms
opeiu, #2, afl-cio
cc: David Donlin, Assistant General Counsel
Attachments
-----FOOTNOTES-----
1 The Wall Street Journal, December 4, 2007, p A1.
2 "Business Roundtable Unveils Principles for Health Care Reform," Press
Release, June 6, 2007,
http://www.businessroundtable.org//newsroom/docurnent.aspx?qs=5886BF807822B0F19D5448322FB51711FCF50
C8. Accessed December 4, 2007.
3 Presentations by Carl Camden, CEO, Kelly Services; Michael Critelli, Chairman
and CEO, Pitney Bowes, Inc.; and Robert Galvin, M.D., Director, Global Health,
General Electric Corporation, at Conference on Business and National Health Care
Reform, sponsored by the Century Foundation and the Commonwealth Fund,
Washington, DC, September 14, 2007.
4 "National Health Care Reform: The Position of the National Business Group on
Health," National Business Group on Health, Washington, DC (July, 2006),
http://www.businessgrouphealth.org/pdfs/ nationalhealthcarereformpositionstatement.pdf.
(Accessed December 4, 2007).
5 The Wall Street Journal, November 13, 2007, p. B4.
6 The New York Times, February 7, 2007.
7 The New York Times, August 31, 2007.
8 The New York Times, September 4, 2002.
9 Verizon Communications, SEC Def. 14A, 2003.
10 The New York Times, October 5, 2007.
11 Correspondence: John J. Sweeney, President, AFL-CIO, and G. Richard Wagoner,
CEO, General Motors Corporation, June 14, 2007 and August 8, 2007.
12 Maher, W.B., "Rekindling ReformHow Goes Business?" 93 Am J Pub Health 92
(2003).
13 Letter and Report to SEC Chairman Christopher Cox from AFL-CIO Office of
Investment Director, Daniel F. Pedrotty, October 4, 2007.
14 The McGraw-Hill Companies:
http://media.corporate-ir.net/media_files/irol/96/96562/Director_Code_Ethics_2008.pdf
(accessed January 30, 2008); American Express Company: email correspondence
between Stephen P. Norman, Corporate Governance Officer and Secretary, The
American Express Company, and Daniel F. Pedrotty, Director, AFL-CIO Office of
Investment, January 3, 2008; Bristol-Meyers Squibb website posting:
http://www.bms.com/sr/key issues/content/data/reform.html; Letter from Heather
L. Maples, Special Counsel, Division of Corporation Finance, U.S. Securities and
Exchange Commission, to Amy L. Goodman, Gibson, Dunn and Crutcher LLP, January
10, 2008; IBM: Letter from Randy MacDonald, Senior Vice President, Human
Resources, IBM Corporation, to Dan Pedrotty, Director, AFL-CIO Office of
Investment. December 12, 2007 (attached); GE: Letter from David N. Stewart,
Senior Counsel, Investigations/Regulatory, General Electric, to Sister Barbara
Kraemer, President, School Sisters of St. Francis of St. Joseph's Convent,
January 25, 2008.
15 Email from David B. Hollander, Legal Manager-Corporate Acquisitions and
Finance, EDS, to Robert E. McGarrah, Jr., Counsel, AFL-CIO Office of Investment,
February 1, 2008.
16 House Committee on Oversight and Government Reform, "Private Medicare Drug
Plans: High Expenses and Low Rebates Increase the Cost of Medicare Drug
Coverage," Washington, DC, October 2007, p.i.
17 Associated Press, December 28, 2007, "Issues rated as `extremely important'
in November [2007], and how that sentiment has changed [in December 2007];
Health care: 48 percent then, 53 percent now." Associated Press-Yahoo News
survey of 1,821 adults was conducted Dec. 14-20, 2007; overall margin of
sampling error of plus or minus 2.3 percentage points. Commonwealth Fund, "The
Public's Views on Health Care Reform in the 2008 Presidential Election," January
15, 2008: 86% of Americans surveyed say health care reform will be "somewhat
important" (24%) or "very important" (62%).
18 "ONE or more Chrysler officers and/or directors SHALL actively support and
lobby for UNIVERSAL HEALTH coverage (sic)..." Chrysler Corporation, 1992 SEC
No-Act. LEXIS 143 (February 10, 1992).
[STAFF REPLY LETTER]
February 12, 2008
Response of the Office of Chief Counsel Division of Corporation Finance
Re: Target Corporation Incoming letter dated January 17, 2008
The proposal requests that the board adopt a policy addressing conflicts of
interest involving board members with health industry affiliations, including
conflicts associated with company involvement in public policy issues related to
these affiliations.
There appears to be some basis for your view that Target may exclude the
proposal under rule 14a-8(i)(7), as relating to Target's ordinary business
operations (i.e., terms of its conflicts of interest policy). Accordingly, we
will not recommend enforcement action to the Commission if Target omits the
proposal from its proxy materials in reliance on rule 14a-8(i)(7). In reaching
this position, we have not found it necessary to address the alternative bases
for omission upon which Target relies.
Sincerely,
/s/
Craig Slivka
Attorney-Adviser
|